References

2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults

2021 · External reference

2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk

10.1016/j.jacc.2022.07.006 · 2022 · External reference

An “Inclisiran First” strategy vs usual care in patients with atherosclerotic cardiovascular disease

10.1016/j.jacc.2024.03.382 · 2024 · External reference

EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study

10.1093/eurjpc/zwaa047 · 2021 · External reference

Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study

10.1016/j.lanepe.2023.100624 · 2023 · External reference

Lipid treatment status and goal attainment among patients with atherosclerotic cardiovascular disease in the United States: a 2019 update

10.1016/j.ajpc.2022.100336 · 2022 · External reference

LDL-C target attainment in secondary prevention of ASCVD in the United States: barriers, consequences of nonachievement, and strategies to reach goals

10.1080/00325481.2022.2117498 · 2022 · External reference

Strategies for the secondary prevention of atherosclerotic cardiovascular disease

10.15420/usc.2024.33 · 2025 · External reference

2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice Guidelines

10.1161/cir.0000000000001457 · 2026 · External reference

AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines

2019 · External reference

2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association/American College of Cardiology Joint Committee on clinical practice guidelines

10.1161/cir.0000000000001168 · 2023 · External reference

2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

10.1093/eurheartj/ehz455 · 2020 · External reference

2024 ESC guidelines for the management of chronic coronary syndromes

10.1093/eurheartj/ehae177 · 2024 · External reference

The discovery of PCSK9 as a pivotal point in the prevention of cardiovascular disease

10.1016/j.ajpc.2025.101314 · 2025 · External reference

Evolocumab and clinical outcomes in patients with cardiovascular disease

10.1056/nejmoa1615664 · 2017 · External reference

Alirocumab and cardiovascular outcomes after acute coronary syndrome

10.1056/nejmoa1801174 · 2018 · External reference

Evolocumab in patients without a previous myocardial infarction or stroke

10.1056/nejmoa2514428 · 2026 · External reference

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events

10.1056/nejmoa1501031 · 2015 · External reference

Efficacy and safety of lerodalcibep in patients with or at high risk of cardiovascular disease: a randomized clinical trial

10.1001/jamacardio.2024.1659 · 2024 · External reference

Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol

10.1056/nejmoa1912387 · 2020 · External reference

Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial

10.1016/s2213-8587(17)30313-3 · 2017 · External reference

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

10.1016/s2213-8587(19)30158-5 · 2019 · External reference

Long-term evolocumab in patients with established atherosclerotic cardiovascular disease

10.1161/circulationaha.122.061620 · 2022 · External reference

Long‐term efficacy, safety, and tolerability of alirocumab in 8242 patients eligible for 3 to 5 years of placebo‐controlled observation in the ODYSSEY OUTCOMES trial

10.1161/jaha.122.029216 · 2023 · External reference

Cognition after lowering LDL-cholesterol with Evolocumab

10.1016/j.jacc.2020.03.039 · 2020 · External reference

Cognitive function in a randomized trial of evolocumab

10.1056/nejmoa1701131 · 2017 · External reference

Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial

10.1001/jama.2016.16951 · 2016 · External reference

Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial

10.1001/jama.2022.5218 · 2022 · External reference

Effect of evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction

10.1016/j.jcmg.2022.03.002 · 2022 · External reference

Inflammation and cholesterol as predictors of cardiovascular events among 13 970 contemporary high-risk patients with statin intolerance

10.1161/circulationaha.123.066213 · 2024 · External reference

Targeting residual inflammatory risk: the next frontier for atherosclerosis treatment and prevention

10.1016/j.vph.2023.107238 · 2023 · External reference

Rosuvastatin to prevent vascular events in men and women with elevated C-Reactive protein

10.1056/nejmoa0807646 · 2008 · External reference

Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction

10.1161/01.cir.0000029743.68247.31 · 2002 · External reference

Beyond lipid lowering: effects of PCSK9 inhibition on inflammation and HDL function

10.1016/j.jacl.2026.02.003 · 2026 · External reference

Intensive lowering of LDL cholesterol levels with evolocumab in autoimmune or inflammatory diseases: an analysis of the FOURIER trial

10.1161/circulationaha.124.072756 · 2025 · External reference

Evidence of an anti-inflammatory effect of PCSK9 inhibitors within the human atherosclerotic plaque

10.1016/j.atherosclerosis.2023.06.971 · 2023 · External reference

Impact of in-hospital PCSK9 inhibition on myocardial inflammation after myocardial infarction: a randomized clinical trial

10.1016/j.jacbts.2025.03.010 · 2025 · External reference

Evolocumab for early reduction of LDL cholesterol levels in patients with acute coronary syndromes (EVOPACS)

10.1016/j.jacc.2019.08.010 · 2019 · External reference

Effects of PCSK9 targeting: alleviating oxidation, inflammation, and atherosclerosis

10.1161/jaha.121.023328 · 2022 · External reference

Clinical benefit of evolocumab by severity and extent of coronary artery disease: analysis from FOURIER

10.1161/circulationaha.118.034309 · 2018 · External reference

Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome

10.1016/j.jacc.2019.10.057 · 2020 · External reference

Peripheral artery disease and venous thromboembolic events after acute coronary syndrome: role of lipoprotein(a) and modification by alirocumab: prespecified analysis of the ODYSSEY OUTCOMES randomized clinical trial

10.1161/circulationaha.120.046524 · 2020 · External reference

Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk)

10.1161/circulationaha.117.032235 · 2018 · External reference

Obesity-associated cardiovascular risk and benefit from PCSK9 inhibition: a prespecified analysis from FOURIER

10.1016/j.jacc.2025.10.036 · 2026 · External reference

Efficacy and safety of very low achieved LDL-cholesterol in patients with prior ischemic stroke

10.1161/circulationaha.125.077549 · 2026 · External reference

Safety and lipid-lowering efficacy of inclisiran monotherapy in patients without ASCVD: the VICTORION-mono randomized clinical trial

10.1016/j.jacc.2025.04.049 · 2025 · External reference

LDL-C management with inclisiran plus usual care vs usual care alone in participants with recent acute coronary syndrome: victorion-inception

10.1016/j.jacl.2025.04.157 · 2025 · External reference

Design and rationale of the VICTORION-difference study: a phase 4 randomized, double-blind, placebo-controlled clinical trial to assess inclisiran's early efficacy, safety, tolerability, as well as its impact on quality of life in individuals with hypercholesterolemia

10.1016/j.ahj.2025.05.014 · 2025 · External reference

Design and rationale of a randomized clinical trial assessing the effect of inclisiran on atherosclerotic plaque in individuals without previous cardiovascular event and without flow- limiting lesions identified in an in-hospital screening: the VICTORION-PLAQUE primary prevention trial

10.1016/j.ahj.2025.08.001 · 2026 · External reference

Oral PCSK9 inhibitors

10.1007/s11883-024-01199-2 · 2024 · External reference

Phase 2b randomized trial of the oral PCSK9 inhibitor MK-0616

10.1016/j.jacc.2023.02.018 · 2023 · External reference

Efficacy and safety of oral PCSK9 inhibitor enlicitide in adults with heterozygous familial hypercholesterolemia: a randomized clinical trial

10.1001/jama.2025.20620 · 2026 · External reference

LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER trial

10.1177/2047487320902750 · 2021 · External reference

PCSK9-targeting drugs and gender: are there any differences?

10.3390/jcm14134469 · 2025 · External reference

Sex differences in efficacy and safety of PCSK9 monoclonal antibodies: a real-world registry

10.1016/j.atherosclerosis.2023.03.013 · 2023 · External reference

Sex differences in LDL-C response to PCSK9 inhibitors: a real world experience

10.1016/j.jacl.2022.12.002 · 2023 · External reference

Sex differences in low-density lipoprotein cholesterol reduction with PCSK9 inhibitors in real-world patients: the LIPID-REAL registry

10.1097/fjc.0000000000001205 · 2022 · External reference

Lower on-treatment low-density lipoprotein cholesterol and major adverse cardiovascular events in women and men: pooled analysis of 10 ODYSSEY phase 3 alirocumab trials

10.1161/jaha.118.009221 · 2018 · External reference

Sex differences in the treatment with PCSK9 monoclonal antibodies-real world experience from a dedicated preventive cardiology clinic

10.1016/j.ajpc.2025.101022 · 2025 · External reference

Sex-specific predictors of PCSK9 levels in a European population: the IMPROVE study

10.1016/j.atherosclerosis.2020.07.014 · 2020 · External reference

Sex difference in circulating PCSK9 and its clinical implications

10.3389/fphar.2022.953845 · 2022 · External reference

Alirocumab and cardiovascular outcomes according to sex and lipoprotein(a) after acute coronary syndrome: a report from the ODYSSEY OUTCOMES study

10.1016/j.jacl.2024.04.122 · 2024 · External reference

Race/ethnic and sex differences in the initiation of Non-statin lipid-lowering medication following myocardial infarction

10.1016/j.jacl.2021.08.001 · 2021 · External reference

Adoption of PCSK9 inhibitors among patients with atherosclerotic disease

10.1161/jaha.120.019331 · 2021 · External reference

Factors associated with PCSK9 inhibitor initiation among US veterans

10.1161/jaha.120.019254 · 2021 · External reference

Effects of evolocumab on low-density lipoprotein cholesterol, non-high density lipoprotein cholesterol, apolipoprotein B, and lipoprotein(a) by race and ethnicity: a meta-analysis of individual participant data from double-blind and open-label extension studies

10.1161/jaha.120.016839 · 2021 · External reference

Predictors of PCSK9 (proprotein convertase Subtilisin/Kexin type 9) inhibitor prescriptions for secondary prevention of clinical atherosclerotic cardiovascular disease

10.1161/circoutcomes.120.007237 · 2021 · External reference

Long-term lipid lowering with evolocumab in older individuals

10.1016/j.jacc.2024.11.019 · 2025 · External reference

Cardiac allograft vasculopathy inhibition with alirocumab: the CAVIAR trial

10.1161/circulationaha.125.077603 · 2026 · External reference

PCSK9 inhibitors: economics and policy

10.1016/j.jacc.2017.10.001 · 2017 · External reference

Cost-effectiveness of alirocumab: a just-in-time analysis based on the ODYSSEY outcomes trial

10.7326/m18-1776 · 2019 · External reference

Cost-effectiveness of alirocumab in patients with acute coronary syndromes: the ODYSSEY OUTCOMES trial

10.1016/j.jacc.2020.03.029 · 2020 · External reference